AbbVie (NYSE: ABBV ) (NEOE: ABBV:CA ) is looking stable on the price action front and dividend yields remain lucrative. However, there are cracks in the buy thesis, even beyond the now aging Humira patent cliff story. In this analysis, I will evaluate whetherI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a for ...